Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
July 17, 2023

Causaly's Impressive Growth Fuels Expansion and Market Domination

Causaly aims to leverage new funding to fuel growth, forge partnerships, and dominate the market

London-based Causaly, a groundbreaking AI and machine learning platform, has successfully raised $60 million in a Series B funding round led by Iconiq Growth. With its ability to rapidly piece together preclinical discoveries, Causaly is poised to reshape the landscape of biomedical research. This significant investment will fuel the company's expansion of commercial relationships and solidify its position in the market, revolutionizing how scientists unravel the complexities of disease biology.

In the fast-paced world of biomedical research, Causaly stands out as a game-changer. Founded in 2018 by Artur Saudabayev and Yiannis Kiachopoulos, this London-based AI and machine learning platform empowers scientists by effortlessly sifting through vast amounts of scientific literature, regulatory documents, clinical trials, and proprietary research. With remarkable speed, Causaly brings together all the critical pieces of preclinical discovery, providing researchers with a comprehensive understanding of the underlying biology of diseases.

The recent Series B funding round, led by Iconiq Growth, marks a significant milestone for Causaly, as it secured a remarkable $60 million investment.This significant financial support will fuel the company's growth, strengthening its leadership position in the industry. The funding round garnered participation from industry giants like Index Ventures, Marathon Venture Capital, Pentech Ventures, EBRD, as well as visionary individuals like Alex Gorsky, former Chairman and CEO of Johnson & Johnson, and Olivier Pomel, CEO and Co-Founder of Datadog, adding weight to Causaly's journey towards innovation and success. Causaly's extraordinary growth is evident, with a threefold increase in revenue and customer base. Its groundbreaking technology has gained traction across the pharmaceutical landscape, with 12 of the top 20 pharma companies already leveraging Causaly's platform. By streamlining and enhancing the research process, Causaly's innovative solution empowers scientists to navigate the complexities of disease biology with unparalleled efficiency and precision.

With $60 million raised in its recent Series B funding round, Causaly is poised to transform the field of biomedical discovery. Powered by cutting-edge AI and machine learning, this London-based company accelerates the research process, providing scientists with an all-encompassing understanding of disease biology. The funding will pave the way for further commercial growth and cement Causaly's market position. As 12 of the top 20 pharma companies embrace Causaly's groundbreaking technology, the future of biomedical research looks promising with new horizons waiting to be explored.

Kiachopoulos said “Recent advances in AI open completely new possibilities, and there is a great need for transparent AI systems that science leaders can trust” “Knowledge is the lifeblood of research organizations, and we are committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.”

Neil Hodgson Coyle
Neil Hodgson-Coyle
Editorial chief at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram